Compare Nvidia Corp (NVDA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Viatris Inc — how do they compare? Nvidia Corp trades at $206.5 (market cap $4.92T), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Nvidia Corp is far larger — about 248.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| NVDA | VTRS | |
|---|---|---|
Market Cap | $4.92T | $19.79B |
Sector | Technology | Health |
52-Week High | $235.75 | $17.39 |
52-Week Low | $165.17 | $8.74 |
Enterprise Value | $4.86T | $32.00B |
Dividend Yield | 0.49% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamentals. Recent earnings beats and robust profitability margins highlight operational strength. The stock is supported by a consensus analyst price target of $325.86, though it faces technical resistance near $210.
Outlook remains positive driven by AI chip demand, but risks include competition and market volatility. Revenue growth acceleration and high institutional ownership suggest long-term potential, yet valuation multiples require sustained execution to justify further upside.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
